Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
906.5 USD | -0.09% | +0.59% | +3.22% |
07:30am | Sanofi Q1 profit slips on generic competition, forex effects | RE |
Apr. 24 | TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.22% | 97.42B | |
-1.51% | 104B | |
+1.86% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B | |
-24.93% | 8.22B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals : , Sanofi Say FDA Has Expanded Approval of Dupixent to Include Children Aged 6 to 11 Years with Moderate-to-Severe Asthma